CommercialCoverageMedium impact
11.01.02s, Cochlear Implantation
Independence Blue Cross·Audiology, ENT (Ear, Nose & Throat), Neurosurgery·Medical Policy
Effective date
Sep 8, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross has expanded cochlear implant coverage to include single-sided deafness (SSD) and asymmetric hearing loss (AHL) in patients age 5+, effective 09/08/2025. Simultaneously, restrictive replacement criteria were removed, and SSD/AHL were moved from experimental/investigational to medically necessary status. Billing teams must update systems to recognize new covered diagnoses and reference the DME repair/replacement policy for component coverage.
Action Required
By 09/08/2025: (1) Billing team must update IBC commercial plan authorization criteria in billing system to recognize H90.41, H90.42 (unilateral sensorineural hearing loss) and asymmetric hearing loss diagnoses as medically necessary for cochlear implant coverage when all clinical criteria are met (age 5+, limited benefit from hearing aids/CROS trial). (2) Remove or deactivate the previous restriction that limited replacement of internal/external components (L8614–L8621) to only individuals with inadequate response; reference policy 05.00.44r for DME repair/replacement guidelines instead. (3) Update prior authorization templates and clinical review tools to reflect SSD/AHL as covered diagnoses rather than experimental. (4) Train billing and authorization staff on new age minimum (5 years) and CROS trial requirement exceptions (aural atresia, microtia grade 2+). Failure to update criteria will result in claim denials for previously non-covered diagnoses and potential patient appeals.